Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Ipilimumab
Related studies linked through entity extraction aliases.
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
- Status
- RECRUITING
- Phase
- PHASE2
CARE1 Pragmatic Clinical Trial
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
- Status
- RECRUITING
- Phase
- PHASE2
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
- Status
- RECRUITING
- Phase
- PHASE2
Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
- Status
- RECRUITING
- Phase
- PHASE3
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
- Status
- RECRUITING
- Phase
- PHASE4
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
- Status
- SUSPENDED
- Phase
- PHASE2
A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2